About us
Polpharma Biologics International (PBI) builds on a strong legacy as a next-generation biosimilar company designed for speed, flexibility, and smart execution.
We don’t operate like a traditional pharma giant – and this is by design. Our lean, highly experienced team is driven by a shared purpose: making high-quality biologics accessible to more people, faster.
We work with a global network of partners while focusing our in-house expertise where it matters most: regulatory strategy, clinical development, CMC, and program leadership. From concept to commercialization, we know how to build, scale, and deliver.
Our VIBE: the way we work
Velocity. Impact. Belonging. Empowerment.
Our values shape how we think, collaborate, and deliver. They guide our decisions, strengthen our partnerships, and keep us focused on expanding access to biologic therapies that are reliable, sustainable, and built to last.
Velocity
We act with focus and urgency – making clear decisions and moving programs forward with purpose
Impact
We prioritize work that expands access and creates meaningful value for patients and healthcare systems.
Belonging
We foster trusted relationships across teams and partners, creating an environment where collaboration drives stronger outcomes.
Empowerment
We place ownership in the hands of experienced people and support them to lead with accountability and confidence.
Why we exist
Who we are
PBI is a biosimilar company focused on advancing high-quality biologic therapies from scientific insight through commercial production – and sustaining their value throughout the product lifecycle.
Operating from Zug, Switzerland, we combine experienced in-house leadership with a globally connected partner network to guide programs with clarity, accountability, and long-term commitment.
Our model is intentionally designed for focus and scalability: we retain critical capabilities internally while collaborating with trusted partners to deliver efficiently at every stage of development and supply.
Built on scientific rigor and disciplined execution, we are committed to expanding patient access to biologic medicines while supporting sustainable healthcare systems worldwide.